NovaBay Pharmaceuticals, Inc. (NBY) Cut to Sell at Zacks Investment Research

Zacks Investment Research cut shares of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) from a hold rating to a sell rating in a research report report published on Saturday, August 5th.

According to Zacks, “NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. “

Several other research firms also recently commented on NBY. Roth Capital set a $6.00 price objective on NovaBay Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, June 20th. Maxim Group reaffirmed a hold rating on shares of NovaBay Pharmaceuticals in a research note on Saturday, May 13th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $7.00.

NovaBay Pharmaceuticals (NYSE:NBY) traded up 1.62% on Friday, reaching $4.70. The company’s stock had a trading volume of 29,698 shares. The stock has a 50-day moving average of $4.17 and a 200-day moving average of $3.66. The stock’s market cap is $71.95 million. NovaBay Pharmaceuticals has a one year low of $2.25 and a one year high of $5.09.

NovaBay Pharmaceuticals (NYSE:NBY) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.01. NovaBay Pharmaceuticals had a negative return on equity of 280.84% and a negative net margin of 108.38%. The firm had revenue of $4.12 million for the quarter, compared to the consensus estimate of $4.57 million. On average, analysts predict that NovaBay Pharmaceuticals will post ($0.46) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “NovaBay Pharmaceuticals, Inc. (NBY) Cut to Sell at Zacks Investment Research” was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.com-unik.info/2017/08/19/zacks-investment-research-downgrades-novabay-pharmaceuticals-inc-nby-to-sell-updated.html.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Get a free copy of the Zacks research report on NovaBay Pharmaceuticals (NBY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for NovaBay Pharmaceuticals (NYSE:NBY)

What are top analysts saying about NovaBay Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NovaBay Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit